Heart failure & cardiomyopathies
Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists
Authors' conclusion
GLP1-RA use in HF patients was significantly associated with reductions in body weight and PAPs at 6 months, despite no changes in GDMT and loop diuretic doses.
Study context
- Population
- Heart failure (HF) patients with a CardioMEMS device who received semaglutide or tirzepatide for at least 6 months during the monitoring period; patients already on GLP-1 RAs prior to device implantation excluded54 years, BMI 41.4 kg/m², 67% men, 44% with EF < 40%, 89% diabetes, 89% semaglutide
- Participants
- 9 patients
- Exposure
- Temporal trends of pulmonary artery pressure (PAP) in HF patients receiving GLP-1 RAs
- GLP-1 RAsn = nine
- Outcome
- Body weight
- Follow-up
- 6 months
Main finding
As reported in the abstract
- Body weight decreased from 123.6 to 117.2 kg
- P = 0.047
Observational data: associations, not effects.
Further findings
Systolic PAP · 6 months
- 38.9 to 34.0 mmHg
- P = 0.045
Diastolic PAP · 6 months
- 20.0 to 17.8 mmHg
- P = 0.019
Mean PAP · 6 months
- 27.3 to 24.3 mmHg
- P = 0.018
Correlation between weight loss and PAP reductions (Pearson)
- Systolic PAP r = 0.69
- P = 0.04
- Mean PAP r = 0.72
- P = 0.029
Median dose of semaglutide (or equivalent) · 6 months
- Median dose
- 0.9 (range 0.25-1) mg/week
Original publication
Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists. ESC Heart Fail. Published 27 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →